GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) — Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology firm growing next-generation vaccines for critical infectious ailments, at this time introduced that it’ll take part in two upcoming investor conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, can be a subject of dialogue in every convention.
|Piper Sandler 32nd Annual Digital Healthcare Convention|
|Tuesday, December 1, 2020|
|Time:||10:00 a.m. Jap Time (ET)|
|Panel title:||The Highway Forward for COVID-19 Vaccines: What We Know and Questions Nonetheless to Be Answered into 2021|
|Moderators:||Edward A. Tenthoff and Yasmeen Rahimi, Ph.D.|
|NVAX Panelist:||Gregory M. Glenn, M.D., President of Analysis and Growth, Novavax
Further panelists: Moderna, Inc., Arcturus Therapeutics Holdings, Inc. and Altimmune, Inc.
This occasion is open to Piper Sandler purchasers
Stanley C. Erck, President and Chief Government Officer, and Dr. Glenn
|Webcast:||A replay of the recorded hearth session is on the market by way of the occasions web page of the Firm’s web site at ir.novavax.com for 90 days.|
Wednesday, December 2, 2020
|Evercore ISI 3rd Annual HealthCONx Convention|
|Date:||Thursday, December 3, 2020|
|Time:||2:15 p.m. Jap Time (ET)|
|Participation:||Hearth chat and investor conferences|
|Dwell webcast:||www.novavax.com, “Investors”/ “Events”|
NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 illness. NVX-CoV2373 was created utilizing Novavax’ recombinant nanoparticle expertise to generate antigen derived from the coronavirus spike (S) protein and accommodates Novavax’ patented saponin-based Matrix-M™ adjuvant to reinforce the immune response and stimulate excessive ranges of neutralizing antibodies. NVX-CoV2373 accommodates purified protein antigen and can’t replicate, nor can it trigger COVID-19. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors focused by the virus, a essential side for efficient vaccine safety. Within the Part 1 portion of its Part 1/2 medical trial, NVX-CoV2373 was usually well-tolerated and elicited strong antibody responses numerically superior to that seen in human convalescent sera. NVX-CoV2373 can also be being evaluated in a Part Three trial within the UK. and two ongoing Part 2 research that started in August; a Part 2b trial in South Africa, and a Part 1/2 continuation within the U.S. and Australia. Novavax has secured $2 billion in funding for its international coronavirus vaccine program, together with as much as $399 million in funding from the Coalition for Epidemic Preparedness Improvements (CEPI) and virtually $1.7 billion from the U.S. authorities.
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology firm that promotes improved well being globally by way of the invention, improvement, and commercialization of progressive vaccines to stop critical infectious ailments. Novavax is at the moment conducting a number of medical trials for NVX-CoV2373, its vaccine candidate towards the virus that causes COVID-19, together with a pivotal Part Three medical trial in the UK to guage the efficacy, security and immunogenicity in people aged 18-84 years of age. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all major targets in its pivotal Part Three medical trial in older adults. Each candidate vaccines incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to reinforce the immune response and stimulate excessive ranges of neutralizing antibodies. Novavax is a number one innovator of recombinant vaccines; its proprietary recombinant expertise platform combines the ability and pace of genetic engineering to effectively produce extremely immunogenic nanoparticles with the intention to handle pressing international well being wants.
For extra data, go to www.novavax.com and join with us on Twitter and LinkedIn.